Dr. Langis Michaud, OD MS
Claim this profileMore about Langis Michaud, OD MS
Clinical Trial Related
1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Langis Michaud, OD MS has experience with
- Myopic Defocus Soft Lens Design (MDSL)
- Single Vision Soft Lens Design (SVSL)
Breakdown of trials Langis Michaud, OD MS has run
Near-sightedness
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Langis Michaud, OD MS specialize in?
Langis Michaud, OD MS focuses on Near-sightedness and Myopia. In particular, much of their work with Near-sightedness has involved treating patients, or patients who are undergoing treatment.
Is Langis Michaud, OD MS currently recruiting for clinical trials?
No, Langis Michaud, OD MS is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Langis Michaud, OD MS has studied deeply?
Yes, Langis Michaud, OD MS has studied treatments such as Myopic defocus soft lens design (MDSL), Single vision soft lens design (SVSL).
What is the best way to schedule an appointment with Langis Michaud, OD MS?
Apply for one of the trials that Langis Michaud, OD MS is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.